Roberto Iacone, Alentis Therapeutics CEO

Alen­tis nabs $181M to broad­en Claud­in's scope in AD­Cs

Swiss biotech Alen­tis Ther­a­peu­tics thinks it can ex­pand the reach of the Claudin fam­i­ly in on­col­o­gy, and half a dozen new in­vestors are help­ing back …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.